Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Efficacy of Sinopharm Vaccine Among Stem Cell Transplant Recipients During Two Peaks of Delta and Omicron variants of COVID-19

Author(s): Ali Ghasemi, Rozita Khodashahi*, Mohsen Aliakbarian, Ebrahim Khaleghi, Baran Razmkhah, Mehrsa Vahdatinia, Mahdi Salimi Far and Omolbanin Bakhti

Volume 18, Issue 4, 2023

Published on: 13 September, 2022

Page: [540 - 546] Pages: 7

DOI: 10.2174/1574886317666220801122822

Price: $65

Abstract

Background: Considering the dearth of research on the complications of Sinopharm coronavirus disease 2019 (COVID-19) vaccine in immunocompromised individuals and the lack of available data on COVID-19 vaccination from Iran.

Objective: This study aimed to investigate the efficacy of vaccine of Sinopharm COVID-19 vaccine and its complications in bone marrow transplant (BMT) recipients.

Methods: This was a retrospective cross-sectional study conducted on 250 patients with BMT who were referred to Montaserieh Hospital, Mashhad, Iran. Among them, 53 cases who received at least two doses of Sinopharm COVID-19 vaccine from March to January 2021 were entered in this study. The data were extracted from a student dissertation (Code:4000370).

Results: Sinopharm vaccine side effects were reported only in 7.7% of the patients, and shingles was the only serious side effect of the Sinopharm vaccine, which was observed only in one case. The results also revealed that Sinopharm COVID-19 vaccine side effects were not related to age or gender. Infection with the Delta variant of COVID-19 was reported in 7.5% (n=4) and no mortality was reported among them. Vaccine failure was reported in 39.6% of the cases; however, no mortality was reported among patients infected with the Omicron variant of COVID-19.

Conclusion: In summary, it seems that Sinopharm COVID-19 vaccine adverse effects were not serious among stem cell transplant recipients. However, it may lead to some severe complications in the population. Vaccine failure against the Delta and Omicron variants of COVID-19 has been reported among more than one-third of BMT patients; however, no mortality was observed among BMT patients infected with the new variants of COVID-19.

Keywords: COVID-19, side effects, transplant, vaccination, sinopharm, stem cell.

« Previous Next »
Graphical Abstract

[1]
Bagcchi S. The world’s largest COVID-19 vaccination campaign. Lancet Infect Dis 2021; 21(3): 323.
[http://dx.doi.org/10.1016/S1473-3099(21)00081-5] [PMID: 33639124]
[2]
Ong E, Wong MU, Huffman A, He Y. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. Front Immunol 2020; 11: 1581.
[http://dx.doi.org/10.3389/fimmu.2020.01581] [PMID: 32719684]
[3]
Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med 2021; 10(7): 1428.
[http://dx.doi.org/10.3390/jcm10071428] [PMID: 33916020]
[4]
Ariamanesh M, Porouhan P, PeyroShabany B, et al. Immunogenicity and safety of the inactivated SARS-CoV-2 vaccine (BBIBP-CorV) in patients with malignancy. Cancer Invest 2022; 40(1): 26-34.
[http://dx.doi.org/10.1080/07357907.2021.1992420] [PMID: 34634986]
[5]
Taghizadeh-Hesary F, Porouhan P, Soroosh D, et al. COVID-19 in cancer and non-cancer patients. Int J Cancer Manag 2021 Apr 30; 14(4): e110907.
[http://dx.doi.org/10.5812/ijcm.110907]
[6]
Fix OK, Blumberg EA, Chang KM, et al. AASLD expert panel consensus statement: Vaccines to prevent covid‐19 infection in patients with liver disease. Hepatology 2021; 74(2): 1049-64.
[7]
Kaplan RM, Milstein A. Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance. Proc Natl Acad Sci USA 2021; 118(10): e2021726118.
[http://dx.doi.org/10.1073/pnas.2021726118] [PMID: 33619178]
[8]
Dodd RH, Pickles K, Nickel B, et al. Concerns and motivations about COVID-19 vaccination. Lancet Infect Dis 2021; 21(2): 161-3.
[http://dx.doi.org/10.1016/S1473-3099(20)30926-9] [PMID: 33338440]
[9]
Wang J, Jing R, Lai X, et al. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines 2020; 8(3): 482.
[http://dx.doi.org/10.3390/vaccines8030482] [PMID: 32867224]
[10]
Iftikhar R, Zaidi U. Interim-Guidelines for COVID-19 Vaccination in Hematological Malignancies and Hematopoietic Stem Cell Transplant Recipients. NJHS 2021 Nov 8; 6(1): 38-43.
[http://dx.doi.org/10.21089/njhs.61.0038]
[11]
Jayadevan R, Shenoy RS, Anithadevi TS. Survey of symptoms following COVID-19 vaccination in India. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.02.08.21251366]
[12]
Hatmal MM, Al-Hatamleh MAI, Olaimat AN, et al. Side effects and perceptions following COVID-19 vaccination in Jordan: A randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines 2021; 9(6): 556.
[http://dx.doi.org/10.3390/vaccines9060556] [PMID: 34073382]
[13]
Oliver SE, Gargano JW, Marin M, et al. The advisory committee on immunization practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine—United States, December 2020. MMWR Morb Mortal Wkly Rep 2020; 69(50): 1922-4.
[http://dx.doi.org/10.15585/mmwr.mm6950e2] [PMID: 33332292]
[14]
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383(27): 2603-15.
[http://dx.doi.org/10.1056/NEJMoa2034577] [PMID: 33301246]
[15]
Giannella M, Pierrotti LC, Helanterä I, Manuel O. SARS-CoV-2 vaccination in solid-organ transplant recipients: What the clinician needs to know. Transpl Int 2021; 34(10): 1776-88.
[http://dx.doi.org/10.1111/tri.14029] [PMID: 34450686]
[16]
Nair V, Jandovitz N, Hirsch JS, et al. An early experience on the effect of solid organ transplant status on hospitalized COVID‐19 patients. Am J Transplant 2021 Jul; 21(7): 2522-31.
[PMID: 33443778]
[17]
Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: Interim analysis of 2 randomized clinical trials. JAMA 2020; 324(10): 951-60.
[http://dx.doi.org/10.1001/jama.2020.15543] [PMID: 32789505]
[18]
WHO, World Health Organization (WHO). WHO, World Health Organization (WHO) evidence assessment: Sinopharm/BBIBP COVID-19 vaccine frbtsagoesoipbtsw. 2021; pp. 1-16. Available from: https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf
[19]
Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol 2020; 11: 585354.
[http://dx.doi.org/10.3389/fimmu.2020.585354] [PMID: 33163000]
[20]
Passamonti F, Cattaneo C, Arcaini L, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: A retrospective, multicentre, cohort study. Lancet Haematol 2020; 7(10): e737-45.
[http://dx.doi.org/10.1016/S2352-3026(20)30251-9] [PMID: 32798473]
[21]
Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21(2): 181-92.
[http://dx.doi.org/10.1016/S1473-3099(20)30843-4] [PMID: 33217362]
[22]
Vályi-Nagy I, Matula Z, Gönczi M, et al. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans. Geroscience 2021; 43(5): 2321-31.
[http://dx.doi.org/10.1007/s11357-021-00471-6] [PMID: 34633612]
[23]
Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA 2021; 325(17): 1784-6.
[http://dx.doi.org/10.1001/jama.2021.4385] [PMID: 33720292]
[24]
Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021; 325(21): 2204-6.
[http://dx.doi.org/10.1001/jama.2021.7489] [PMID: 33950155]
[25]
Benotmane I, Gautier G, Perrin P, et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA 2021; 326(11): 1063-5.
[http://dx.doi.org/10.1001/jama.2021.12339] [PMID: 34297036]
[26]
Chevallier P, Coste-Burel M, Le Bourgeois A, et al. Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients. EJHaem 2021; 2(3): 520-4.
[http://dx.doi.org/10.1002/jha2.242] [PMID: 34226903]
[27]
Le Bourgeois A, Coste-Burel M, Guillaume T, et al. Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant. JAMA Network Open 2021; 4(9): 2126344.
[http://dx.doi.org/10.1001/jamanetworkopen.2021.26344]
[28]
Ali H, Ngo D, Aribi A, et al. Safety and tolerability of SARS-CoV2 emergency-use authorized vaccines for allogeneic hematopoietic stem cell transplant recipients transplantation and cellular therapy 2021; 27(11): 1-6.
[29]
Rozita Khodashahia MA, Mahin Ghorban S, Kambiz Akhavan R, et al. Complications and efficacy of Sinopharm vaccine among liver and kidney transplantation. Curr Drug Saf 2022. Available from: https://pubmed.ncbi.nlm.nih.gov/35249504/
[30]
Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis 2021; 111: 219-26.
[http://dx.doi.org/10.1016/j.ijid.2021.08.013] [PMID: 34384899]
[31]
El-Shitany NA, Harakeh S, Badr-Eldin SM, et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. Int J Gen Med 2021; 14: 1389-401.
[http://dx.doi.org/10.2147/IJGM.S310497] [PMID: 33907443]
[32]
Riad A, Abdulqader H, Morgado M, et al. Global prevalence and drivers of dental students’ COVID-19 vaccine hesitancy. Vaccines (Basel) 2021; 9(6): 566.
[http://dx.doi.org/10.3390/vaccines9060566] [PMID: 34072500]
[33]
FaHBF, Food and Health Bureau (FHB). Report on Evaluation of Safety EaQoCC-VVCIAohw 2021. Available from: https://www.fhb.gov.hk/en/press_and_publications/press/2022.html
[34]
Pulliam JR, Van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa. MedRxiv 2022; 376(6593): eabn4947.

Rights & Permissions Print Cite
Article Metrics
4
© 2024 Bentham Science Publishers | Privacy Policy